AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

9/26/24 4:05:00 PM ET

Pharmaceuticals and Biotechnology

Health Care

Get the next $ABCL alert in real time by email

AbCellera (NASDAQ:ABCL) will announce its third quarter 2024 financial results on Monday, November 4, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240926882302/en/

Get the next $ABCL alert in real time by email

Date	Price Target	Rating	Analyst
8/20/2024		Buy → Hold	The Benchmark Company
2/22/2024	$9.00	Hold → Buy	The Benchmark Company
12/5/2023	$6.00	Overweight	KeyBanc Capital Markets
11/6/2023		Buy → Hold	The Benchmark Company
10/13/2023	$20.00	Overweight	Piper Sandler
2/28/2023		Outperform	Cowen
12/15/2022	$30.00	Buy	Goldman
11/16/2022	$29.00	Buy	Truist

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Chat with this insight

Recent Analyst Ratings for $ABCL

$ABCL Market Insights

Live Market Insights

Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $5

Keybanc Maintains Overweight on AbCellera Biologics, Lowers Price Target to $7

AbCellera Biologics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate, Sales $9.954M Miss $10.836M Estimate

$ABCL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Hansen Carl L. G. exercised 56,125 shares at a strike of $2.70, increasing direct ownership by 7% to 841,875 units (SEC Form 4)

Large owner Thermopylae Holdings Ltd. bought $739,977 worth of shares (283,516 units at $2.61), increasing direct ownership by 0.51% to 56,086,009 units (SEC Form 4)

Chief Operating Officer Lecault Veronique exercised 83,334 shares at a strike of $0.19, increasing direct ownership by 4% to 2,123,456 units (SEC Form 4)

$ABCL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Thermopylae Holdings Ltd. bought $739,977 worth of shares (283,516 units at $2.61), increasing direct ownership by 0.51% to 56,086,009 units (SEC Form 4)

Montalbano John S. bought $137,400 worth of shares (30,000 units at $4.58), increasing direct ownership by 54% to 86,000 units (SEC Form 4)

Hayden Michael R bought $98,200 worth of shares (20,000 units at $4.91) (SEC Form 4)

$ABCL SEC Filings

SEC Form 10-Q filed by AbCellera Biologics Inc.

AbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by AbCellera Biologics Inc.

$ABCL Press Releases

Fastest customizable press release news feed in the world

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Reports Q3 2024 Business Results

$ABCL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

SEC Form SC 13G filed by AbCellera Biologics Inc.

SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

$ABCL Financials

Live finance-specific insights

AbCellera Reports Q3 2024 Business Results

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera Reports Q2 2024 Business Results

$ABCL Leadership Updates

Live Leadership Updates

AbCellera Announces Resignation of Board Member

DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

AbCellera Announces Changes to Its Board of Directors

$ABCL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

AbCellera Biologics downgraded by The Benchmark Company

AbCellera Biologics upgraded by The Benchmark Company with a new price target

KeyBanc Capital Markets initiated coverage on AbCellera Biologics with a new price target

Recent Analyst Ratings for
$ABCL

$ABCL
Market Insights

$ABCL
Insider Trading

$ABCL
Insider Purchases

$ABCL
SEC Filings

$ABCL
Press Releases

$ABCL
Large Ownership Changes

$ABCL
Financials

$ABCL
Leadership Updates

$ABCL
Analyst Ratings